Newsletter N.2, May 2022

This Project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 945118

Evolution of

Resilience

During January, the first patient was enrolled in the project's clinical trial, since then, the number of patients enrolled has gradually increased. We are glad to share with our patients our project Resilience with the aim of preventing anthracycline-induced cardiotoxicity with our remote ischemic conditioning intervention.

MORE INFO

RESILIENCE Talks

Leaders of the future

In RESILIENCE is leading WP2, the Work Package dedicated to the clinical trial.

Interview with Alberto López-García, Foundation Jiménez Díaz University Hospital (IIS-FJD).

Alberto is a young researcher leading WP2, the Work Package dedicated to the clinical trial. He represents the young community of the project. One of the goals of RESILIENCE is to identify the European leaders of the future.

Could you tell us a bit about yourself?
I obtained my Bachelor of Medicine degree from the Complutense University of Madrid and specialized in hematology at Clínico San Carlos University Hospital. Since then, I obtained University Master's degree in Lymphoma and Bone marrow transplantation at the CEU San Carlos University and Valencia University respectively.

I specialized in the treatment and diagnosis of patients with lymphoma in Foundation Jiménez Díaz University Hospital and since then, Cardio-oncology has been one of my fields of interest, presenting my first project of Cardiac toxicity of Anthracyclines in older patients with lymphoma in the annual American congress of Hematology (ASH) in 2019. As a result, I obtained my certification in cardio-oncology by ICOS in 2021 and I am currently pursuing an University degree in Cardioncology at the CEU San Carlos University.

MORE INFO

Scientific

Advances

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity

There is a strong need to identify (bio)markers that can detect early stages of anthracycline-induced cardiotoxicity (AIC). In this editorial, 2 RESILIENCE researchers present the current state of the art of the field. They discuss data from al original paper published in the same issue of the journal by Bonny Ky´s team, showing that paraoxonase-1 (PON-1) appears a potential circulating biomarker of AIC in breat cancer patients. In this editorial, RESILIENCE project is presented as one of the most promising ongoing endeavors in the quest for the identification of sensitive markers of early AIC.

MORE INFO

First encounters with patients

A few weeks ago we conducted interviews with the first patients in the trial. You will soon be able to see them on our social networks and in the next newsletter.

Important

News

Opening of a new center: Hospital Ramón y Cajal.

On 29 April we opened a new center where the clinical trial of the Resilience project is being carried out.

Latest

Videos

Do you want to know how to use the device?

Click on the video to watch it!

Novel mitochondria-targeted therapies for cancer treatment-induced cardiotoxicity.

Click on the video to watch it!

RESILIENCE´s Scientific Advisory Board (SAB)

MORE INFO

The party responsible for the processing of your personal data is Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) (hereinafter, CNIC), with Fiscal Identification Code (C.I.F.) G-82316753 and domiciled at calle Melchor Fernández Almagro, 3, 28029 Madrid.We inform that the ownership of the web domain https://resilience-h2020.com/ (hereinafter, the “Website”), belongs to CNIC.The personal data that you provide, either through this Website, through any form/application in paper format or by any other means, will be duly registered and incorporated into CNIC’s data processing systems.Email for information: resilience@cnic.esContact details of the Data Protection Officer: dpo@cnic.es